The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in ...

Schwab's FNDB ETF has balanced sector exposure, value tilt, multi-cap coverage, and consistent dividend growth. Read here for more analysis.

Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...

Charles Schwab’s total client assets hit $11.8 trillion as of the end of November, up 15% from the same period last year.

Analysts spotlight fresh insights on Visa, Schwab and Amphenol, with new data on growth drivers, risks and market performance ...

Battle lines are being drawn in the brokerage industry. Charles Schwab, which pioneered the low-cost brokerage business in the 1970s, is now part of an establishment that leads with wealth management, ...

The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything.

However, focusing on tech hasn't been bad at all for investors. In three years, the Invesco fund has risen by 123%, which is ...

Guggenheim analyst Seamus Fernandez upgraded Bristol-Myers Squibb Company (NYSE: BMY) from Neutral to Buy and announced a $62 ...

Amid the final four weeks of the NFL season, many teams have shifted their focus to the offseason. But what does this entail ...

Charles Schwab (SCHW) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fintel reports that on December 10, 2025, HSBC upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy. Analyst Price ...